Retraction notice to "microRNA-107 functions as a candidate tumor suppressor gene in renal clear cell carcinoma involving multiple genes" [Urologic Oncology: Seminars and Original Investigations 33 (2015) 205.e1-205.e11] [0.03%]
有关“microRNA-107在肾透明细胞癌中的作用”一文的撤稿声明[Urologic Oncology: Seminars and Original Investigations 33 (2015) 205.e1-205.e11]
Nan Song,Xin Ma,Hongzhao Li et al.
Nan Song et al.
Diagnostic performance of urinary tumor DNA in urothelial carcinoma: A systematic review and network meta-analysis [0.03%]
尿液肿瘤DNA诊断膀胱癌系统评价和网络meta分析
Shugo Yajima,Naoki Imasato,Tadayoshi Hashimoto et al.
Shugo Yajima et al.
Accurate, non-invasive detection of urothelial carcinoma (UC) remains an unmet clinical need. Urinary tumor DNA (utDNA) assays have recently emerged as promising tools, but their comparative diagnostic performance across assay types remains...
Epigenetic signatures and risk determinants in bladder cancer: Implications for diagnostic and therapeutic interventions [0.03%]
膀胱癌的表观遗传特征和风险因素:对诊断和治疗干预的影响
Bhagyashree Pradhan,Prahallad Mishra,Pujarini Dash et al.
Bhagyashree Pradhan et al.
Within the broader urological landscape, bladder cancer (BC) continues to be a resilient malignancy, characterised by a burgeoning prevalence and an intricate etiological framework involving both genetic and environmental determinants. The ...
Partial gland ablation for radio-recurrent prostate cancer: Short-term oncological and functional outcomes [0.03%]
前列腺放疗复发后的部分腺体消融治疗的短期疗效及功能评估结果
Luis G Medina,Masatomo Kaneko,Lorenzo Storino Ramacciotti et al.
Luis G Medina et al.
Introduction and objective: To assess outcomes and complications of partial gland cryoablation (sCRYO) and high-intensity focused ultrasound (sHIFU) for localized radio-recurrent prostate cancer (CaP). ...
Adverse pathology and low tumor volume in biopsy Gleason 3 + 4 prostate cancer: Toward safe expansion of active surveillance and focal therapy [0.03%]
格里森评分3+4前列腺癌活检的不良病理和低肿瘤体积:安全扩大积极监测和局部治疗的方向
Yu Ozawa,Marcio Covas Moschovas,Marco Sandri et al.
Yu Ozawa et al.
Introduction: The criteria for active surveillance and focal therapy in Gleason score (GS) 3 + 4 disease remain unclear. We aimed to refine them by evaluating predictors of adverse pathology and low-volume disease at radi...
New CPT codes for prostate biopsy improve alignment of reimbursement with evidence-based practice [0.03%]
新的前列腺活检CPT编码促进与基于证据的实践相一致的报销制度改革
Alec Zhu,Ashwin Ramaswamy,Ashutosh K Tewari et al.
Alec Zhu et al.
Effective PD-1 checkpoint blockade in bladder cancer model requires tumor-draining lymph nodes and lymphocyte trafficking [0.03%]
有效的PD-1检查点阻滞需要肿瘤引流淋巴结和淋巴细胞转运来对抗膀胱癌模型中的免疫逃逸现象
Juan C Angulo-Lozano,Lina Posada-Calderon,Huixian Liu et al.
Juan C Angulo-Lozano et al.
Introduction: Tumor-draining lymph nodes (tdLNs) are key hubs for antitumor T-cell priming. However, their contribution to PD-1 checkpoint blockade in bladder cancer remains poorly defined. In this study, we investigated ...
Impact of intraoperative intravenous heparin bolus on clinical outcomes during radical nephrectomy and IVC tumor thrombectomy in renal cell carcinoma with level I-IV IVC thrombus: A multi-institutional study [0.03%]
术中大剂量静脉注射肝素对肾细胞癌合并一级至四级下腔静脉血栓患者根治性肾切除术和肿瘤取血管手术临床疗效的影响:一项多中心研究
Ahmet Murat Aydin,Alireza Dehghanmanshadi,Vaneeza Mukhtar et al.
Ahmet Murat Aydin et al.
Purpose: Intraoperative intravenous heparin bolus (IHB) is variably administered prior to inferior vena cava (IVC) cross-clamping during radical nephrectomy (RN) and IVC tumor thrombectomy (TT) for level I or higher throm...
Salvage lymph node dissection in oligo-recurrent prostate cancer patients: Mapping patterns of recurrence and factors associated with disease progression [0.03%]
前列腺癌寡转移患者挽救性淋巴结清扫术:复发模式及影响疾病进展因素分析
Mohamed E Ahmed,Eman E Ahmed,Milad Bonakdarhashemi et al.
Mohamed E Ahmed et al.
Background and objective: Salvage lymph node dissection (sLND) is a treatment for prostate cancer patients with lymph node recurrence. However, there is a lack of comprehensive data regarding subsequent patterns of recurr...
Rare genitourinary cancers: Spotlight on an unmet need in urologic oncology [0.03%]
罕见泌尿生殖系统癌症:关注泌尿学肿瘤学中的一个未满足需求
Benjamin T Ristau,Philippe E Spiess
Benjamin T Ristau